Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

The stock's rise snapped a three-day losing streak.

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. On Thursday, April 3rd, the host of ...

Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close. The end of the earnings season is always a good time ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex and Alnylam are seen as most resilient ... Morningstar reports that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...